RxSight Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Year Ended December 31,
	2024	2023	2022
Operating Activities:
Net loss	$(27,455)	$(48,608)	$(66,756)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,575	4,078	3,884
Provision for bad debts	34	—	—
Amortization of right-of-use lease assets	49	165	138
Amortization of debt issuance costs and premium	—	287	552
Loss on extinguishment of debt	—	1,769	—
Amortization of discount on short-term investments	(8,977)	(6,122)	(1,405)
Stock-based compensation	24,635	15,746	11,397
Provision for excess and obsolete inventory	404	164	752
Change in operating assets and liabilities:
Accounts receivable	(9,803)	(9,325)	(6,094)
Inventories	(4,993)	(2,749)	(7,555)
Prepaid and other assets	(1,230)	(562)	789
Accounts payable	946	1,250	635
Accrued expenses and other liabilities	5,869	2,314	4,813
Net cash used in operating activities	(16,946)	(41,593)	(58,850)
Investing Activities:
Purchase of property and equipment	(5,440)	(4,814)	(2,393)
Maturity of short-term investments	243,000	255,000	255,000
Purchases of short-term investments	(336,871)	(272,315)	(212,657)
Net cash (used in) provided by investing activities	(99,311)	(22,129)	39,950
Financing Activities:
Proceeds from term loan	—	20,000	—
Repayment of term loan	—	(60,000)	—
Proceeds from issuance of common stock from public offering	108,100	54,050	—
Proceeds from issuance of common stock from at-the-market offerings	—	42,434	6,050
Proceeds from issuance of common stock	20,816	9,473	1,778
Payments for employee taxes related to stock compensation	(4,768)	(1,423)	(643)
Principal payments on finance lease liabilities	(61)	(153)	(121)
Payments of deferred offering costs	(768)	(622)	(587)
Payments of debt issuance costs	—	(2,235)	(145)
Net cash provided by financing activities	123,319	61,524	6,332
Effect of foreign exchange rate on cash, cash equivalents and restricted cash	(9)	6	(9)
Net increase (decrease) in cash, cash equivalents and restricted cash	7,053	(2,192)	(12,577)
Cash, cash equivalents and restricted cash - beginning of period	10,403	12,595	25,172
Cash, cash equivalents and restricted cash - end of period	$17,456	$10,403	$12,595
Supplemental disclosure of cash flow information:
Operating cash flows from operating leases	2,154	2,216	2,187
Cash paid for income taxes	24	8	3
Cash paid for interest on financing leases	21	12	18
Cash paid for interest on term loan	—	3,464	4,239
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations:
Operating lease	10,016	46	1,090
Finance lease	19	102	311
Lease obligations recorded for right-of-use assets:
Operating lease	10,016	46	1,090
Finance lease	19	102	311
Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities	545	282	299
Deferred offering and financing costs included in accounts payable and accrued liabilities	—	145	133
Reclassification of deferred financing costs	768	1,390	90

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.